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It has become increasingly clear that we have made important
progress in understanding the immune response to various
pathogens, including fungi. This may soon be translated to the
development of effective approaches for modulating the
immune system against invasive fungal infections (IFIs). What
do immunomodulation and immunotherapy mean for the
future of effective IFI management? During the last several
decades, a growing population of immunocompromised
patients has emerged, including patients with haematological
malignancies, solid organ transplant recipients, patients with
AIDS, those hospitalized in intensive-care units who undergo
aggressive instrumental interventions and prolonged treat-
ment with broad-spectrum antibacterials, premature infants,
and patients with underlying conditions, such as diabetes mell-
itus, ketoacidosis, and iron overload. Despite the advent of
newer antifungal agents and advances in critical care and sur-
gical management, IFIs constitute a leading cause of morbidity
and mortality, especially in immunocompromised patients [1].
Among fungal pathogens, Candida, Aspergillus and Cryptococcus
spp. are responsible for the bulk of IFIs, and other fungi that
are less common but have a worldwide distribution, such as
Rhizopus, Mucor, Lichtheimia (formerly Absidia), Fusarium and
Scedosporium spp. signiﬁcantly contribute to IFI morbidity and
mortality [2,3]. Given the limitations of the current antifungal
armamentarium, manipulations aimed at the host immune
response appear to constitute a rational approach.
The papers presented in this theme section review impor-
tant aspects of work on the immunotherapy of IFI, including
mucocutaneous and invasive candidiasis, invasive aspergillosis,
cryptococcosis, and other infections caused by more rare ﬁl-
amentous fungi, such as mucormycosis, fusariosis, and sce-
dosporiosis.
Van de Veerdonk et al. [4] describe the role of recombi-
nant cytokines in the treatment of disseminated candidiasis.
They ﬁrst present an updated overview of the mechanisms
behind the pathogenesis of Candida infections, providing the
rationale for the use of adjuvant immunotherapy, and then
present up-to-date data of studies in animal models or
humans with a focus on the use of recombinant cytokines as
a strategy to improve antifungal host defence.
The review by Carvalho et al. [5] highlights the conceptual
advances made in our knowledge of cellular and immunologi-
cal mechanisms, and how this knowledge could be exploited
for the successful design of immunotherapeutic interventions
against aspergillosis. They underline the fact that the pro-
gress in understanding the pathogenesis of fungal infections
through the integration of immunological and genetic data
will pay dividends in clinical practice.
Antachopoulos and Walsh [6] present an overview of
immune responses against Cryptococcus, and discuss the
effects of immunomodulatory agents, mainly cytokines and
monoclonal antibodies, that have been extensively studied
in vitro and in vivo. In view of the Th1–Th2 balance concept,
the question that arises is: are all patients with cryptococcal
disease likely to beneﬁt from immunomodulatory treatment?
The authors conclude that, despite the progress made, the
currently published clinical data on the adjunctive use of
immunotherapy in patients with cryptococcal infections are
too limited to lead to ﬁrm recommendations.
The fourth paper [7] reviews the immunotherapeutic
options for treating infections with rare ﬁlamentous fungi,
such as Zygomycetes, Scedosporium and Fusarium spp. Among
the immunotherapeutic agents, cytokines, including inter-
feron-c, granulocyte–macrophage colony-stimulating factor,
and granulocyte colony-stimulating factor, and granulocyte
transfusion therapy, have shown the most promising results
in ex vivo experiments, animal studies, case reports, and small
case series.
All of the reviews recapitulate the usefulness of sufﬁciently
powered studies on the role of new immunotherapeutic
agents against IFI. Clinical trials are needed to clarify some
controversial issues, such as dosing, timing of immunomodu-
latory intervention, and the patient groups that would
receive the most beneﬁt.
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